VYGRVoyager Therapeutics, Inc.
3.390USD-0.59%Mkt Cap: 208.88M $P/E: —3d ago
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibod…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap208.88M $
Enterprise Value120.80M $
Revenue (TTM)34.46M $
Gross Profit-81.60M $
Net Income (TTM)-119.72M $
Revenue/Share0.5800 USD
Last Price3.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92915B1061
Valuation
P/E (Trailing)—
P/E (Forward)-2.60
PEG—
EV/EBITDA-1.10
EV/Revenue3.51
P/S5.94
P/B1.15
EPS (TTM)-1.76
EPS (Forward)-1.28
52W Range
2.93517% of range5.550
52W High5.550 USD
52W Low2.935 USD
Profitability
Gross Margin-236.81%
Oper. Margin-833.87%
EBITDA Margin0.00%
Profit Margin-296.53%
ROE-61.06%
ROA-47.46%
Growth
Revenue Growth-39.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.47M $
CapEx (TTM)2.60M $
FCF Margin-224.35%
FCF Yield-37.01%
Net Debt-83.77M $
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.19
Current Ratio7.50
Quick Ratio7.16
Book Value/Sh2.880 USD
Cash/Share1.888 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.89 USD
Upside (mean)+339.2%
Target Range8.000 USD – 25.00 USD
$8.000+339.2% to mean$25.00
# Analysts9
Ownership
Shares Out.61.62M
Float44.47M
Insiders14.84%
Institutions57.87%
Short Interest
Short Ratio5.1d
Short % Float6.92%
Short % Out.5.91%
Shares Short3.64M
Short (prev mo.)3.57M
Technical
SMA 503.345 (+1.3%)
SMA 2003.817 (-11.2%)
Beta1.31
S&P 52W Chg18.16%
Avg Vol (30d)566.69K
Avg Vol (10d)474.01K
Technical Indicators
RSI (14)57.7
MACD0.0032
MACD Signal-0.0437
MACD Hist.+0.0469
BB Upper3.391 USD
BB Middle3.160 USD
BB Lower2.929 USD
BB Width14.63%
ATR (14)0.1576 USD
Vol Ratio (20d)0.85x